PCN35 ECONOMIC EVALUATION OF CYCLOPHOSPHAMIDE, DOXORUBICIN, VINCRISTINE AND PREDNISONE (CHOP) CHEMOTHERAPY REGIME WITH OR WITHOUT RITUXIMAB (R) IN THE 2ND LINE TREATMENT OF FOLLICULAR NON-HODGIN LYMPHOMA
Abstract
Authors
EJ Soini JA Martikainen T Nousiainen